Reference : Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-bl...
Scientific journals : Article
Human health sciences : Immunology & infectious disease
http://hdl.handle.net/2268/71471
Recombinant gp350 vaccine for infectious mononucleosis: A phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults
English
Sokal, E. M. [> > > >]
Hoppenbrouwers, K. [> > > >]
Vandermeulen, C. [> > > >]
Moutschen, Michel mailto [Université de Liège - ULg > Département des sciences cliniques > Immunopathologie - Transplantation]
Leonard, Philippe mailto [Centre Hospitalier Universitaire de Liège - CHU > > Maladies infectieuses et médecine interne générale >]
Moreels, A. [> > > >]
Haumont, M. [> > > >]
Bollen, A. [> > > >]
Smets, F. [> > > >]
Denis, M. [> > > >]
15-Dec-2007
Journal of Infectious Diseases
Univ Chicago Press
196
12
1749-1753
Yes (verified by ORBi)
International
0022-1899
Chicago
[en] Background. To date, there is no commercially available vaccine to prevent infectious mononucleosis, a disease frequently induced by Epstein-Barr virus (EBV) infection in adolescents or adults devoid of preexisting immunity to the virus. Methods. A total of 181 EBV-seronegative, healthy, young adult volunteers were randomized in a double-blind fashion to receive either placebo or a recombinant EBV subunit glycoprotein 350 (gp350)/aluminum hydroxide and 3-O-desacyl-4'-monophosphoryl lipid A (AS04) candidate vaccine in a 3-dose regimen. Results. The vaccine had demonstrable efficacy (mean efficacy rate, 78.0% [95% confidence interval {CI}, 1.0% -96.0%]) in preventing the development of infectious mononucleosis induced by EBV infection, but it had no efficacy in preventing asymptomatic EBV infection. One month after receipt of the final dose of gp350 vaccine, 98.7% of subjects showed seroconversion to anti-gp350 antibodies (95% CI, 85.5%-97.9%), and they remained anti-gp350 antibody positive for > 18 months. Furthermore, there were no concerns regarding the safety or reactogenicity of the gp350/AS04 vaccine. Conclusion. These data support the clinical feasibility of using an EBV vaccine to prevent infectious mononucleosis.
http://hdl.handle.net/2268/71471

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Recombinant gp350 vaccine for infectious mononucleosis - 2007.pdfAuthor postprint110.25 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.